All In Biotech

Data reports

FDA novel drug approvals in 2026: the full list so far, with trends

Every FDA novel drug approval in 2026 so far: 53 new molecular entities and biologics through November 17, with dates, ingredients, approved uses and trends.

By the All In Biotech editorial team · Published November 18, 2026 · 7 min read

FDA's Center for Drug Evaluation and Research (CDER) approved 53 novel drugs between January 1 and November 17, 2026. That is already more than the full-year totals for 2021, 2022, 2024 and 2025, and two fewer than 2023. The full list is below, with dates, active ingredients and a short description of each approved use.

The figures come from this site's copy of FDA's Novel Drug Approvals pages, as of November 2026. FDA updates that list as approvals happen, so the count will change before the year ends.

What counts as a novel drug approval

A novel approval is a new molecular entity (NME) approved through a new drug application (NDA), or a new therapeutic biologic approved through a biologics license application (BLA), whose active ingredient has never been approved in the United States. CDER publishes one list per year.

Three points matter when reading the count:

  • It covers CDER only. Most vaccines, blood products and cell and gene therapies are approved by FDA's Center for Biologics Evaluation and Research (CBER) and do not appear here.
  • New uses for existing drugs, new formulations and new combinations of previously approved ingredients are not novel approvals. Those show up as efficacy supplements or other approvals on /approvals.
  • A biosimilar is not a novel approval, even though it is a new BLA.

Year-over-year count

YearCDER novel approvals
202150
202236
202355
202450
202546
2026 (through Nov 17)53

The 2026 figure is partial. Approvals in the last six weeks of a year can add several more names, so comparisons with full prior years are only provisional until FDA's list closes.

The full 2026 list so far

Uses are shortened from FDA's descriptions. Check the label for the exact approved indication, which often includes conditions on prior therapy, age or biomarker status.

DateDrugIngredientApproved use
2026-01-12Zycubocopper histidinateMenkes disease
2026-02-12AdqueydifamilastMild to moderate atopic dermatitis
2026-02-20BysantimilsaperidoneSchizophrenia and bipolar I manic or mixed episodes
2026-02-23Loargyspegzilarginase-nblnHyperarginemia in arginase 1 deficiency
2026-02-27YuviwelnavepegritideLinear growth in children with achondroplasia
2026-03-17IcotydeicotrokinraModerate-to-severe plaque psoriasis
2026-03-17LynavoylinerixibatCholestatic pruritus in primary biliary cholangitis
2026-03-24Avlayahtividenofusp alfa-eknmHunter syndrome (MPS II)
2026-03-25LifyorlirelacorilantPlatinum-resistant ovarian, fallopian tube or peritoneal cancer
2026-03-26Awiqliinsulin icodec-abaeGlycemic control in type 2 diabetes
2026-04-01FoundayoorforglipronChronic weight management
2026-04-20Idvynsodoravirine and islatravirHIV-1 switch regimen in suppressed adults
2026-05-01VeppanuvepdegestrantER+/HER2- ESR1-mutated advanced breast cancer
2026-05-13BeqalzisonrotoclaxRelapsed or refractory mantle cell lymphoma
2026-05-15BaxfendybaxdrostatHypertension, with other antihypertensives
2026-05-22Hepcludexbulevirtide-gmodChronic hepatitis delta
2026-05-27Decnupazpivekimab sunirine-pvzyBlastic plasmacytoid dendritic cell neoplasm
2026-05-29CypsedocipepofolInduction of general anesthesia
2026-05-29XocovaensitrelvirCOVID-19 post-exposure prophylaxis
2026-05-29Zaynichcefepime and zidebactamComplicated urinary tract infections
2026-06-12AmbelvistgadoquatraneMRI contrast for lesions with abnormal vascularity
2026-06-17Utebzitebipenem pivoxilComplicated urinary tract infections (oral)
2026-06-26Lumvoaveligrotug-vvzeThyroid eye disease
2026-07-07Trutaknaatacicept-vymjProteinuria in IgA nephropathy
2026-07-14RevtorpykgedatolisibHR+/HER2- advanced breast cancer without PIK3CA mutation
2026-07-15Lipfendraenlicitide decanoateLowering LDL cholesterol
2026-07-22JideytrozidesamtinibROS1-positive NSCLC after a ROS1 inhibitor
2026-07-24SimtriyocentanafadineADHD
2026-07-24Lytenavabevacizumab-vikgWet age-related macular degeneration
2026-08-05OrzeyfuloveporextonNarcolepsy type 1
2026-08-13ZenbexusiberdomideMultiple myeloma after at least one prior line
2026-08-13Tauklarifyflorquinitau F 18Tau PET imaging in suspected Alzheimer disease
2026-08-19Pasatrugaretosmab-grtsFibrodysplasia ossificans progressiva
2026-08-26RasonquedaraxonrasibMetastatic pancreatic cancer
2026-08-27LisrayabrepocitinibDermatomyositis
2026-08-28MimrylorusfertideErythrocytosis in polycythemia vera
2026-09-03ZanvastrozilganersenAlexander disease
2026-09-04EtcamahcamizestrantHR+/HER2- breast cancer with ESR1 mutation
2026-09-11Pixclarafloretyrosine F 18PET imaging of recurrent or progressive glioma
2026-09-11Isembyldapitegromab-mstnSpinal muscular atrophy, with SMN2-targeted therapy
2026-09-23LyrfigtulirafugratinibFGFR2-altered cholangiocarcinoma
2026-09-23Onswikinsulin efsitora alfa-gobeGlycemic control in type 2 diabetes
2026-09-25AtebriozzilurgisertibFibrodysplasia ossificans progressiva
2026-09-25JuvmotavapadonParkinson's disease
2026-09-28EmcitatetiratricolPeripheral thyrotoxicosis in MCT8 deficiency
2026-10-09HovilpripritelivirRefractory herpes simplex in immunocompromised adults
2026-10-20HibsagobepirovirsenChronic hepatitis B, with antiviral therapy
2026-11-09SunharboasundexianStroke risk reduction after mild-to-moderate stroke or high-risk TIA
2026-11-13Klygefagefurulimab-gaksAChR antibody-positive generalized myasthenia gravis
2026-11-13PimjetmipimicotinibTenosynovial giant cell tumor
2026-11-16WilserdlygiredestrantER+/HER2- ESR1-mutated advanced breast cancer
2026-11-17LembazadrabetadexSevere Niemann-Pick disease type C
2026-11-17NelkarmineladalkibALK-positive NSCLC after prior therapy

Patterns in the 2026 data

These observations come only from the list above and from the designation flags in this site's data. They describe what has been approved, not why.

Timing across the year

Approvals were uneven by month: 1 in January, 4 in February, 5 in March, 2 in April, 8 in May, 3 in June, 6 in July, 7 in August, 9 in September, 2 in October and 6 in the first 17 days of November. Monthly counts depend on when individual review clocks end, so a busy or quiet month says little on its own. For how those target dates are set, see what is a PDUFA date.

Therapeutic mix

  • Cancer: 13 of the 53 approvals treat a cancer or tumor, counting tenosynovial giant cell tumor. Four are for hormone receptor-positive, HER2-negative breast cancer, and three of those four are limited to tumors with an ESR1 mutation (Veppanu, Etcamah, Wilserdly). Two are for non-small cell lung cancer with a specific driver (ROS1 and ALK).
  • Infectious disease: 7 approvals, covering HIV-1, hepatitis B, hepatitis delta, COVID-19 prophylaxis, herpes simplex and two for complicated urinary tract infections.
  • Cardiometabolic: two once-weekly insulins for type 2 diabetes (Awiqli and Onswik), an oral weight-management drug (Foundayo), an add-on blood pressure drug (Baxfendy), an LDL cholesterol-lowering drug (Lipfendra) and a stroke-prevention drug (Sunharbo).
  • Neurology and psychiatry: schizophrenia and bipolar I disorder, ADHD, narcolepsy type 1, Parkinson's disease, spinal muscular atrophy, Alexander disease and generalized myasthenia gravis.
  • Diagnostic imaging agents: three, an MRI contrast agent and two PET tracers (tau imaging and glioma imaging).
  • Rare genetic and metabolic diseases: several, including Menkes disease, arginase 1 deficiency, achondroplasia, Hunter syndrome, MCT8 deficiency and Niemann-Pick disease type C. Two separate drugs were approved for fibrodysplasia ossificans progressiva within about five weeks of each other.

Orphan, priority and biologic shares

Of the 48 approvals this site has matched to Drugs@FDA application records so far, 23 (about 48%) carry an orphan marking, 31 (about 65%) had priority review and 11 are BLAs. The other five approvals (three of them from the past week) had not yet been matched to a record in the Drugs@FDA download used for this report.

FDA's breakthrough therapy and accelerated approval lists, which this site tracks on /designations, currently run through June 30, 2026. To that date they include 6 breakthrough approvals and 5 accelerated approvals among 2026 novel drugs. Those numbers will rise when FDA updates the lists. Orphan status is explained in orphan drug designation explained, and the expedited programs are compared in breakthrough, fast track, accelerated approval and priority review.

How to research any drug on the list

Each novel approval links to a drug page on this site once the application appears in Drugs@FDA. A drug page brings together:

  • the current label's approved uses and any boxed warning,
  • the approval history with FDA's letters and label PDFs,
  • registered trials from ClinicalTrials.gov,
  • adverse event reports from FAERS,
  • Medicare spending, once CMS data covers the drug (newly approved drugs will not appear in Medicare data for a year or more).

To see every drug for a disease, not just this year's, use the condition search. For example, breast cancer and non-small cell lung cancer list all brand-name drugs whose labels name those cancers.

Where the official list lives

FDA's Novel Drug Approvals page links to each year's table and to CDER's annual summary reports. Labels for each product are on DailyMed and in Drugs@FDA. For approvals of vaccines and cell and gene therapies, check CBER's pages on fda.gov.

Frequently asked questions

How many novel drugs has FDA approved in 2026?
FDA's Center for Drug Evaluation and Research (CDER) listed 53 novel drug approvals from January 1 through November 17, 2026.
What counts as a novel drug approval?
A novel approval is a drug or therapeutic biologic whose active ingredient has never been approved in the United States before, as listed on CDER's Novel Drug Approvals page.
Are vaccines and gene therapies included in the count?
No. CDER's list does not include most vaccines, blood products and cell and gene therapies, which are approved by FDA's Center for Biologics Evaluation and Research (CBER).
What share of 2026 novel approvals are orphan drugs?
Of the 48 approvals this site matched to Drugs@FDA records, 23 carry an orphan marking and 31 had priority review.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading